The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 19, 2024

Filed:

Dec. 13, 2022
Applicant:

Akagera Medicines, Inc., Boxford, MA (US);

Inventors:

Daryl C. Drummond, Lincoln, MA (US);

Suresh K. Tipparaju, Arlington, MA (US);

Charles O. Noble, San Francisco, CA (US);

Alexander Koshkaryev, Newton, MA (US);

Dmitri B. Kirpotin, San Francisco, CA (US);

Assignee:

Akagera Medicines, Inc., Boxford, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 413/14 (2006.01); A61K 9/127 (2006.01); A61K 47/02 (2006.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01); A61K 47/28 (2006.01); C07D 413/10 (2006.01);
U.S. Cl.
CPC ...
C07D 413/14 (2013.01); A61K 9/127 (2013.01); A61K 9/1271 (2013.01); A61K 9/1272 (2013.01); A61K 9/1277 (2013.01); A61K 9/1278 (2013.01); A61K 47/02 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/28 (2013.01); C07D 413/10 (2013.01);
Abstract

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.


Find Patent Forward Citations

Loading…